Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05544929
Title	A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	skin melanoma colorectal cancer triple-receptor negative breast cancer anal squamous cell carcinoma ovarian serous carcinoma thymic carcinoma lung non-small cell carcinoma clear cell renal cell carcinoma gastroesophageal cancer head and neck squamous cell carcinoma malignant mesothelioma nasopharynx carcinoma
Therapies	KFA115 KFA115 + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| ITA \| ESP \| DEU \| CAN